Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2014 · 10-Q
Revenue$935.00K$935.00K+116.6% vs Q1 2013 Net Income-$8.10M-$8.10MN/M vs Q1 2013 EPS Diluted-$0.14-$0.14N/M vs Q1 2013 Gross Profit$934,721+116.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$10,357,271N/M Free Cash Flowderived-$10,589,192N/M Margins · derivedGross margin100.0%−0.0 pt vs Q1 2013
Operating margin-1191.2%+749.8 pt vs Q1 2013
Net margin-866.2%+921.8 pt vs Q1 2013
ended Mar 31, 2014 · filed May 12, 2014 · 42 d after period end